Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Cao, Zhongwei ^a   Fu, Biao ^b   Deng, Biao ^a   Zeng, Yue ^a   Wan, Xinjian ^a   Qu, Lei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Department of geratology Huangshi Central Hospital   (China)

Author keywords

CXCL1; HCC; Invasion; Prognosis; Proliferation

Indexed keywords

ALPHA FETOPROTEIN; CXCL1 CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIGEL; MESSENGER RNA; SYNAPTOTAGMIN I;

ADULT; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; MTT ASSAY; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; UPREGULATION; WESTERN BLOTTING;

EID: 84909988155     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-014-0086-8     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10. Gut 2013, 62(11):1667-1668. 10.1136/gutjnl-2013-305164, 23708586.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142(6):1264-1273. 10.1053/j.gastro.2011.12.061, 22537432.
4. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27(9):1485-1491. 10.1200/JCO.2008.20.7753, 19224838.
5. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009, 373(9664):614-616. 10.1016/S0140-6736(09)60381-0, 19231618.
6. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012, 56(Suppl 1):S75-S87. 10.1016/S0168-8278(12)60009-9, 22300468.
7. Singh R, Lillard JJ, Singh S. Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed) 2011, 3:1569-1582. 10.2741/246.
8. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu JS. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010, 16(15):3875-3886. 10.1158/1078-0432.CCR-10-0483, 20505188.
9. Bondurant KL, Lundgreen A, Herrick JS, Kadlubar S, Wolff RK, Slattery ML. Interleukin genes and associations with colon and rectal cancer risk and overall survival. Int J Cancer 2013, 132(4):905-915. 10.1002/ijc.27660, 22674296.
10. Haskill S, Peace A, Morris J, Sporn SA, Anisowicz A, Lee SW, Smith T, Martin G, Ralph P, Sager R. Identification of three related human GRO genes encoding cytokine functions. Proc Natl Acad Sci U S A 1990, 87(19):7732-7736. 10.1073/pnas.87.19.7732, 2217207.
11. Zhang K, Tian L, Liu L, Feng Y, Dong YB, Li B, Shang DS, Fang WG, Cao YP, Chen YH. CXCL1 contributes to beta-amyloid-induced transendothelial migration of monocytes in Alzheimer's disease. PLoS One 2013, 8(8):e72744. 10.1371/journal.pone.0072744, 23967336.
12. Miyake M, Goodison S, Urquidi V, Gomes GE, Rosser CJ. Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab Invest 2013, 93(7):768-778. 10.1038/labinvest.2013.71, 23732813.
13. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002, 72(1):9-18. 12101257.
14. Vazquez-Martin A, Colomer R, Menendez JA. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer 2007, 43(7):1117-1124. 10.1016/j.ejca.2007.01.037, 17379503.
15. Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, Rosser CJ. Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers. BMC Cancer 2013, 13:322. 10.1186/1471-2407-13-322, 23815949.
16. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch 2005, 446(5):475-482. 10.1007/s00428-005-1264-9, 15856292.
17. Qu L, Deng B, Zeng Y, Cao Z. Decreased expression of the Nkx28 gene correlates with tumor progression and a poor prognosis in HCC cancer. Cancer Cell Int 2014, 14:28. 10.1186/1475-2867-14-28, 24678995.
18. Kuo PL, Shen KH, Hung SH, Hsu YL. CXCL1/GROalpha increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-kappaB/HDAC1 epigenetic regulation. Carcinogenesis 2012, 33(12):2477-2487. 10.1093/carcin/bgs299, 23027620.
19. Amiri KI, Ha HC, Smulson ME, Richmond A. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Oncogene 2006, 25(59):7714-7722. 10.1038/sj.onc.1209751, 16799643.
20. Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin KH. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol 2011, 22(10):2267-2276. 10.1093/annonc/mdq739, 21343381.
21. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005, 23(24):5746-5756. 10.1200/JCO.2005.01.598, 16110031.
22. Baird AM, Gray SG, O'Byrne KJ. Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. PLoS One 2011, 6(1):e14593. 10.1371/journal.pone.0014593, 21298036.
23. Verbeke H, Struyf S, Laureys G, Van Damme J. The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev 2011, 22(5-6):345-358. 10.1016/j.cytogfr.2011.09.002, 22000992.
24. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010, 29(3):405-434. 10.1007/s10555-010-9235-2, 20737283.
25. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl):S81-S96. 10.1016/S0092-8674(02)00703-1, 11983155.